TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9640366

Group type: EXPERIMENTAL
Intervention: R alpha methylhistamine (RAMHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thioperamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Substance P
Number of subjects: 0
Study: 8127531

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (20 micrograms ethinyl estradiol plus 0.15 mg desogestrel)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Oligomenorrheic women
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: OC-treated women
Number of subjects: 81
Study: 2758778

Group type: EXPERIMENTAL
Intervention: ADFR therapy (phosphorus 1.5 gr/day during 3 days, followed by SCT 100 UI/day during 10 days and calcium 1 gr/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 412489

Group type: EXPERIMENTAL
Intervention: 2% cromolyn sodium eye drops
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30884195

Group type: EXPERIMENTAL
Intervention: Sutureless transscleral intraocular lens (IOL) fixation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Retropupillary iris-claw lens fixation
Number of subjects: 30
Study: 28326899

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicines (CAM) and non‐pharmacological interventions (NPI)
Number of subjects: 202638

Group type: EXPERIMENTAL
Intervention: Herbal therapies
Number of subjects: 202638

Group type: EXPERIMENTAL
Intervention: Vitamins
Number of subjects: 202638

Group type: EXPERIMENTAL
Intervention: Lifestyle approaches
Number of subjects: 202638

Group type: EXPERIMENTAL
Intervention: Phytoestrogens
Number of subjects: 202638

Group type: EXPERIMENTAL
Intervention: Higher education, Black ethnicity, MHT or previous oral contraceptive pill use
Number of subjects: 202638

Group type: EXPERIMENTAL
Intervention: Less hopeful about their future
Number of subjects: 202638
Study: 26383005

Group type: EXPERIMENTAL
Intervention: Saphenous vein (SV) Y-composite grafts
Number of subjects: 116

Group type: COMPARATOR
Intervention: Right internal thoracic artery (RITA) Y-composite grafts
Number of subjects: 116
Study: 25034667

Group type: EXPERIMENTAL
Intervention: CLA (Clarinol A‐80; n = 18)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (PLA; sunflower oil; n = 16)
Number of subjects: 34
Study: 23083114

Group type: EXPERIMENTAL
Intervention: Phenylbutazone (PBZ) at 4.4 mg/kg PO q12h day 1, 2.2 mg/kg PO q12h for 4 days, 2.2 mg/kg PO q24h for 9 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Meloxicam at 0.6 mg/kg q24h, 1.8 mg/kg q24h, 3.0 mg/kg q24h
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 19552662

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)‐fortified salt intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-intervention surveillance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Detailed Mf survey and child antigenaemia (Ag) survey in 2006
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-intervention findings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term effects of DEC intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted intervention measures
Number of subjects: 0
Study: 17706714

Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg orally twice daily)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (1 gm orally twice daily)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Vitamin E plus Propionyl-L-carnitine (300 mg and 1 gm orally twice daily)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo (similar regimen)
Number of subjects: 236
Study: 15530629

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 6825
Study: 11520815

Group type: EXPERIMENTAL
Intervention: Thalidomide with induction chemotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (induction chemotherapy without thalidomide)
Number of subjects: 100
Study: 9765724

Group type: EXPERIMENTAL
Intervention: Vinorelbine in combination with cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vinorelbine alone
Number of subjects: 0
Study: 8432129

Group type: EXPERIMENTAL
Intervention: Intrapleural bupivacaine (0.5 percent)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 20
Study: 2890666

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocturnal dosing
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg nocturnal dosing
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29947833

Group type: EXPERIMENTAL
Intervention: Intravenous tirofiban injection and tirofiban injection via a TA catheter to the infarcted coronary artery after aspiration (Group A)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Intravenous tirofiban injection only (Group B)
Number of subjects: 122
Study: 28620891

Group type: EXPERIMENTAL
Intervention: Olaratumab plus doxorubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 0
Study: 27147391

Group type: EXPERIMENTAL
Intervention: Patient-centred intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32
Study: 24667994

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%/timolol 0.5% preservative-free (PF) ophthalmic solution
Number of subjects: 561

Group type: COMPARATOR
Intervention: Bimatoprost 0.03%/timolol 0.5% ophthalmic solution
Number of subjects: 561
Study: 22641790

Group type: EXPERIMENTAL
Intervention: FLU-FOBT Program (linking FOBT provision to influenza vaccination)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: FLU-FOBT Program
Number of subjects: 41
Study: 19902242

Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Strength exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 15
Study: 18792649

Group type: EXPERIMENTAL
Intervention: Color Stroop task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotion Stroop task
Number of subjects: 0
Study: 15682562

Group type: EXPERIMENTAL
Intervention: OptiZen (polysorbate 80 0.5%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Visine Original (tetrahydrozoline HCl 0.05%)
Number of subjects: 50
Study: 12870162

Group type: EXPERIMENTAL
Intervention: Combination treatment (metformin 400 to 2,400 mg/d + glibenclamide 2.5 to 15 mg/d)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Metformin alone (500 to 3,000 mg/d)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Glibenclamide alone (5 to 15 mg/d)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Combination treatment vs Metformin alone
Number of subjects: 88

Group type: COMPARATOR
Intervention: Combination treatment vs Glibenclamide alone
Number of subjects: 88
Study: 10510105

Group type: EXPERIMENTAL
Intervention: SR alfuzosin (5 mg twice daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: SR alfuzosin
Number of subjects: 81
Study: 9071060

Group type: EXPERIMENTAL
Intervention: Alternative and novel activity presentations
Number of subjects: 315

Group type: COMPARATOR
Intervention: Traditional drug abuse prevention program activities
Number of subjects: 315
Study: 1568518

Group type: EXPERIMENTAL
Intervention: Rifamycin SV (525 mg weekly for 10 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pefloxacin (560 mg weekly for 10 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of Rifamycin SV vs Pefloxacin
Number of subjects: 40
Study: 3902550

Group type: EXPERIMENTAL
Intervention: Golytely preparation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 70
Study: 31337413

Group type: EXPERIMENTAL
Intervention: Learning Clubs intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29342492

Group type: EXPERIMENTAL
Intervention: RFA combined with biliary stenting (RFA + stent group; n = 32)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Biliary stent only (stent‐only group; n = 33)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: RFA combined with biliary stenting (RFA + stent group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Biliary stent only (stent‐only group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study: 27268605

Group type: EXPERIMENTAL
Intervention: Standard interferon (IFN) therapy combined with ribavirin (3 MIU three times a week and 800-1200 mg/day) for six months
Number of subjects: 51
Study: 26244389

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitor (PI/r)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: X4 HIV variants
Number of subjects: 141
Study: 23711611

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 706

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 706
Study: 20625011

Group type: EXPERIMENTAL
Intervention: couple‐focused Eban HIV/STD risk‐reduction intervention
Number of subjects: 1070

Group type: COMPARATOR
Intervention: attention‐matched individual‐focused health promotion comparison
Number of subjects: 1070
Study: 18431575

Group type: EXPERIMENTAL
Intervention: Gd-Bopta
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gd-Dota
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both contrast materials
Number of subjects: 10
Study: 16637753

Group type: EXPERIMENTAL
Intervention: Fearful faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Happy faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anxiety levels
Number of subjects: 0
Study: 12783630

Group type: EXPERIMENTAL
Intervention: Propranolol CR (Innopran XL) 160 mg single dose at 10 pm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sustained-release propranolol, single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol CR and sustained-release propranolol, multiple dosing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol CR and sustained-release propranolol, final dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol CR and sustained-release propranolol, bioavailability
Number of subjects: 0
Study: 11186500

Group type: EXPERIMENTAL
Intervention: Case-managed group
Number of subjects: 317

Group type: COMPARATOR
Intervention: Regular-care group
Number of subjects: 317
Study: 8784645

Group type: COMPARATOR
Intervention: Venlafaxine (dosage not specified, administered twice or three times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1312853

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Captopril 50 mg, twice daily for 5 days (pretreatment)
Number of subjects: 8
Study: 6547414

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g 4 times daily for 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carbenoxolone (50 mg 4 times daily for 8 weeks)
Number of subjects: 30
Study: 31046174

Group type: EXPERIMENTAL
Intervention: 3Q-positives (individuals who screened positive to at least one of the 3Q/TMD questions)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 3Q-positives
Number of subjects: 300

Group type: COMPARATOR
Intervention: 3Q-negatives (age and gender matched control group)
Number of subjects: 300
Study: 28939682

Group type: EXPERIMENTAL
Intervention: Pioglitazone (target 45 mg daily)
Number of subjects: 3398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3398

Group type: COMPARATOR
Intervention: Comparison between Pioglitazone and Placebo
Number of subjects: 3398
Study: 27402183

Group type: EXPERIMENTAL
Intervention: Xbox Kinect™ activities (15min) + self‐directed physiotherapy exercises (15min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physiotherapy (self‐directed exercises for 30min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Xbox Kinect™ activities + self‐directed physiotherapy exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 30
Study: 25233652

Group type: EXPERIMENTAL
Intervention: Jin three-needle therapy combined with MOTOmed intelligent motor training
Number of subjects: 80

Group type: COMPARATOR
Intervention: MOTOmed and conventional rehabilitation training (Control)
Number of subjects: 80
Study: 22484337

Group type: EXPERIMENTAL
Intervention: Internet coping skills training program
Number of subjects: 300

Group type: COMPARATOR
Intervention: Internet diabetes education (control condition)
Number of subjects: 300
Study: 19424890

Group type: EXPERIMENTAL
Intervention: Direct intensive speech and language therapy weekly over an 8-month period
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nursery-based model of intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 24
Study: 17622517

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15619563

Group type: EXPERIMENTAL
Intervention: Tinospora cordifolia (TC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 12177654

Group type: EXPERIMENTAL
Intervention: Downsloping ST-segment morphology
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Horizontal ST-segment morphology
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: No ischemic electrocardiographic response
Number of subjects: 64
Study: 10398549

Group type: EXPERIMENTAL
Intervention: Intensive blood glucose control using sulphonylureas or insulin therapy or metformin in overweight patients
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Intensive blood glucose control
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control with captopril
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Blood glucose control
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Drugs or insulin used for blood glucose control
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 5000
Study: 7769811

Group type: EXPERIMENTAL
Intervention: bisoprolol (single oral dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 1905672

Group type: EXPERIMENTAL
Intervention: Amino acid based feed
Number of subjects: 24

Group type: COMPARATOR
Intervention: Whole protein feed
Number of subjects: 24

Group type: COMPARATOR
Intervention: Whole protein feed (after crossover)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amino acid based feed (after crossover)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enteral feeding (general)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Solid food introduction
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Reintroduction of green vegetables
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Return to enteral feed after relapse from green vegetables
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Reintroduction of low residue diet after remission
Number of subjects: 24
Study: 6307777

Group type: COMPARATOR
Intervention: Normal diet according to age
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 200 ml of fresh human milk per day
Number of subjects: 28
Study: 30312214

Group type: EXPERIMENTAL
Intervention: Exercise training (OSAT group, n = 20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nontrained (OSANT group, n = 21)
Number of subjects: 41
Study: 29427059

Group type: EXPERIMENTAL
Intervention: ArthroPlanner software for surgical planning
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group without planning
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: ArthroPlanner software
Number of subjects: 58
Study: 27320956

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Number of subjects: 592
Study: 24266733

Group type: EXPERIMENTAL
Intervention: Short-term cardiac rehabilitation (CR) program for 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 30
Study: 23300664

Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 112
Study: 20422817

Group type: EXPERIMENTAL
Intervention: Antegrade perfusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Retrograde perfusion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 80
Study: 17396040

Group type: EXPERIMENTAL
Intervention: Step-by-step rehabilitation programme (group A: 3-week rehabilitation plus 1-week sojourn at 4 and 8 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional rehabilitation programme (group B: 4-week stay, no further interventions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Step-by-step rehabilitation programme (group A)
Number of subjects: 0
Study: 15791520

Group type: EXPERIMENTAL
Intervention: Indinavir (500 mg/m2 every 8 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ritonavir (liquid formulation)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ritonavir
Number of subjects: 50
Study: 11929641

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs) with 50 microg ethinyl estradiol (EE)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs) with 30-40 microg ethinyl estradiol (EE)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs) with 20 microg ethinyl estradiol (EE)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Progestin-only pills
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Oral contraceptives with second-generation progestins (levonorgestrel or norgestimate) and 20-30 microg EE
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Oral contraceptives with third-generation progestins (desogestrel or gestodene) and 20-30 microg EE
Number of subjects: 626

Group type: COMPARATOR
Intervention: Comparison of third-generation to second-generation progestins
Number of subjects: 626
Study: 10212716

Group type: EXPERIMENTAL
Intervention: Sub-Tenon's block with 2% lignocaine 1 ml containing 150 i.u. per ml of hyaluronidase with 2% plain lignocaine 2 ml and 0.5% plain bupivacaine 2 ml
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sub-Tenon's block with 2% plain lignocaine 3 ml with 0.5% plain bupivacaine 2 ml
Number of subjects: 120
Study: 8540977

Group type: EXPERIMENTAL
Intervention: Standard supplements (for groups 1 and 2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Increased supplements (group 3)
Number of subjects: 16
Study: 2215985

Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/kg and Ketamine 1 mg/kg i.v.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol 2.5 mg/kg and Fentanyl 1.5 micrograms/kg
Number of subjects: 40
Study: 7000226

Group type: EXPERIMENTAL
Intervention: 1 g of metronidazole intra-rectally 1 h preoperatively
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 31192722

Group type: EXPERIMENTAL
Intervention: Music Therapy (n = 16)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Story Telling (n = 15)
Number of subjects: 31
Study: 28693614

Group type: EXPERIMENTAL
Intervention: Increasing access to treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Physical restraint
Number of subjects: 35

Group type: COMPARATOR
Intervention: Lack of care options
Number of subjects: 35
Study: 26093793

Group type: EXPERIMENTAL
Intervention: Docetaxel plus bevacizumab (DB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: S-1 plus bevacizumab (SB)
Number of subjects: 90
Study: 24659022

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study: 22980289

Group type: EXPERIMENTAL
Intervention: Single-balloon enteroscopy (SBE)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Double-balloon enteroscopy (DBE)
Number of subjects: 107
Study: 19335905

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 2193
Study: 17967712

Group type: COMPARATOR
Intervention: Oxidized regenerated cellulose/collagen biomaterial (Promogran)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Autologous growth factors delivered by Gravitational Platelet Separation System (GPS)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of oxidized regenerated cellulose/collagen biomaterial and autologous growth factors
Number of subjects: 51
Study: 15595249

Group type: COMPARATOR
Intervention: Control group (102 patients without pituitary pathology)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Patients with sellar lesions (100 patients)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Operated patients (52 patients)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: BS positive patients (37 patients)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: RAH positive patients (28 patients)
Number of subjects: 202
Study: 11259796

Group type: EXPERIMENTAL
Intervention: Patients with chronic fatigue syndrome (CFS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 11541426

Group type: EXPERIMENTAL
Intervention: Inflated cuffs on the upper part of thighs and arms, performed 12 hours/day during bedrest
Number of subjects: 12

Group type: COMPARATOR
Intervention: No countermeasures applied (control group)
Number of subjects: 12
Study: 7835898

Group type: EXPERIMENTAL
Intervention: Younger AD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older AD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control brains (younger)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control brains (older)
Number of subjects: 0
Study: 3202098

Group type: EXPERIMENTAL
Intervention: Low copper diet for 11 weeks
Number of subjects: 0
Study: 29426287

Group type: EXPERIMENTAL
Intervention: Preoperative rectus sheath block (RSB) with 0.5% ropivacaine hydrochloride
Number of subjects: 61

Group type: COMPARATOR
Intervention: Postoperative rectus sheath block (RSB) with saline
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Preoperative rectus sheath block (RSB)
Number of subjects: 61
Study: 26138736

Group type: EXPERIMENTAL
Intervention: Annual sputum cytology/cytometry testing
Number of subjects: 1568

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 1568